Alabama CRS

Running trials

• Active, not recruiting

  Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.

  NCT06332339· Phase 1· Source

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI

  NCT05079451· Phase 1· Source

• Completed

  To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV

  NCT05854381· Phase 1· Source

• Completed

  Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV

  NCT05471076· Phase 1· Source

• Completed

  Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)

  NCT05099965· Phase 2· Source

• Completed

  B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B

  NCT04193189· Phase 3· Source

• Completed

  Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

  NCT04177355· Phase 1· Source

• Completed

  Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

  NCT03739996· Phase 2· Source

• Completed

  The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

  NCT03635788· Phase 3· Source

• Completed

  Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

  NCT02720094· Phase 2/3· Source